This content is from: Premium

Tiger Cubs Poised to Benefit From This Covid-Related IPO

AbCellera, which has developed a treatment for Covid-19, set terms this week for its IPO.

Tiger Management-related hedge funds Viking Global Investors and Falcon Edge Capital stand to benefit from the initial public offering of AbCellera Biologics, the company that with Eli Lilly has developed an antibody treatment for Covid-19.AbCellera, which recently received emergency use authorization from the Food and Drug Administration, disclosed in a regulatory

To continue reading, subscribe now to Premium Journalism. Already a subscriber? Login.

Related Content